Synonyms: AMR-69 | Esbriet®
pirfenidone is an approved drug (EMA (2011), FDA (2014))
Compound class:
Synthetic organic
Comment: Pirfenidone is an anti-fibrotic drug. In addition to its proven anti-fibrotic effects in lung tissue, pirfenidone-induced in vitro and in vivo anti-fibrotic activity has been reported in experimental liver and renal fibrosis [3,5].
SARS-CoV-2: COVID-19 is accompanied by inflammation and fibrotic lung damage that appears to persist beyond immediate recovery. The clinical potential for applying the antifibrotic activity of pirfenidone to help treat COVID-19-related pulmonary fibrosis is reviewed by Ferrara et al. (2020) [2]. |
|
Bioactivity Comments |
As the precise MMOA of this drug is not fully understood, we are unable to define a primary drug target. |